ABCL

AbCellera Biologics Inc. is a technology company that discovers and develops antibody-based therapeutics through its integrated artificial intelligence-powered drug discovery platform. Headquartered in Vancouver, Canada, the company combines advanced microfluidics, high-throughput screening, machine learning, and genomics to search through millions of natural immune cells and identify antibodies that can be developed into medicines. AbCellera partners with pharmaceutical and biotechnology companies to accelerate antibody discovery programs, with partners including Eli Lilly, Moderna, GSK, and others across oncology, metabolic disease, and infectious disease indications. The company gained prominence through its partnership with Eli Lilly to develop bamlanivimab, one of the first antibody treatments for COVID-19, progressing from initial discovery to emergency use authorization in under a year. AbCellera operates a 380,000 square-foot research and manufacturing facility in Vancouver and employs approximately 400 people. The company went public on NASDAQ in December 2020. Its business model generates revenue through research fees, milestone payments, and royalties on successfully commercialized antibodies discovered using its platform. AbCellera maintains an active internal pipeline of wholly-owned programs in addition to its partnered collaborations, and continues to expand its platform capabilities through ongoing investments in automation, data science, and laboratory infrastructure to increase the speed and success rate of antibody drug development.